Activation of systemic antitumor immunity via TRAIL-induced apoptosis

TNF-related apoptosis-inducing ligand (TRAIL) continues to be intently studied as a cancer therapeutic because of its selective tumoricial activity. We have been interesting in evaluating the ability of TRAIL to induce systemic antitumor immunity through the generation of apoptotic tumor cells. Rece...

Descripción completa

Detalles Bibliográficos
Autores principales: James, Britnie R., Griffith, Thomas S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2012
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494637/
https://www.ncbi.nlm.nih.gov/pubmed/23170271
http://dx.doi.org/10.4161/onci.20638
_version_ 1782249420247531520
author James, Britnie R.
Griffith, Thomas S.
author_facet James, Britnie R.
Griffith, Thomas S.
author_sort James, Britnie R.
collection PubMed
description TNF-related apoptosis-inducing ligand (TRAIL) continues to be intently studied as a cancer therapeutic because of its selective tumoricial activity. We have been interesting in evaluating the ability of TRAIL to induce systemic antitumor immunity through the generation of apoptotic tumor cells. Recent observations suggest that localized administration of TRAIL in combination with CpG ODN generates a systemic antitumor immune response to eliminate the primary tumor and distant metastases.
format Online
Article
Text
id pubmed-3494637
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-34946372012-11-20 Activation of systemic antitumor immunity via TRAIL-induced apoptosis James, Britnie R. Griffith, Thomas S. Oncoimmunology Author's View TNF-related apoptosis-inducing ligand (TRAIL) continues to be intently studied as a cancer therapeutic because of its selective tumoricial activity. We have been interesting in evaluating the ability of TRAIL to induce systemic antitumor immunity through the generation of apoptotic tumor cells. Recent observations suggest that localized administration of TRAIL in combination with CpG ODN generates a systemic antitumor immune response to eliminate the primary tumor and distant metastases. Landes Bioscience 2012-10-01 /pmc/articles/PMC3494637/ /pubmed/23170271 http://dx.doi.org/10.4161/onci.20638 Text en Copyright © 2012 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
James, Britnie R.
Griffith, Thomas S.
Activation of systemic antitumor immunity via TRAIL-induced apoptosis
title Activation of systemic antitumor immunity via TRAIL-induced apoptosis
title_full Activation of systemic antitumor immunity via TRAIL-induced apoptosis
title_fullStr Activation of systemic antitumor immunity via TRAIL-induced apoptosis
title_full_unstemmed Activation of systemic antitumor immunity via TRAIL-induced apoptosis
title_short Activation of systemic antitumor immunity via TRAIL-induced apoptosis
title_sort activation of systemic antitumor immunity via trail-induced apoptosis
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494637/
https://www.ncbi.nlm.nih.gov/pubmed/23170271
http://dx.doi.org/10.4161/onci.20638
work_keys_str_mv AT jamesbritnier activationofsystemicantitumorimmunityviatrailinducedapoptosis
AT griffiththomass activationofsystemicantitumorimmunityviatrailinducedapoptosis

Ejemplares similares